On Tuesday shares of General Electric Company (NYSE:GE) closed at $26.92. Company’s sales growth for last 5 years was -0.80% and EPS growth for next 5 years is recorded as 9.03%. General Electric Co. (NYSE:GE), partnered up with chip-maker Qualcomm, is testing and preparing to market light bulbs which can track a person’s location in a store’s aisles.
Hercules Offshore, Inc. (NASDAQ:HERO) in last trading activity moved up 3.73% to close at $0.94. Company weekly performance is 34.84% while its quarterly performance stands at 6.06%. Hercules Offshore, Inc. (NASDAQ:HERO) is -81.31% away from its 52 week high. On 30 April, Hercules Offshore, Inc. (NASDAQ:HERO) announced that it has received a notice from Saudi Aramco extending the termination date of its drilling contract for the Hercules 261, to May 31, 2015.
On last trading day Ericsson (NASDAQ:ERIC) moved down -1.00% to close at $10.86. Its volatility for the week is 1.50% while volatility for the month is 1.55%. ERIC’s sales growth for past 5 years was 2.00% and its EPS growth for past 5 years was 25.20%. Ericsson (NASDAQ:ERIC) monthly performance is -12.21%. Ericsson (NASDAQ:ERIC) and Ernst and Young (EY) recently launched a Growth Codes report that looks at the evolvement of operators in respect of their networks and their business models.
Alcatel Lucent SA (ADR) (NYSE:ALU) has institutional ownership stands at 4.70%. In last trading activity company’s stock closed at $3.47. CounterPath announced a collaboration with Alcatel-Lucent SA (ADR) (NYSE:ALU) to offer large enterprise technologies enabling communications services over virtually any network, device or application.
On last trading day MacroGenics, Inc. (NASDAQ:MGNX) decreased -8.61% to close at $27.17. Its volatility for the week is 7.73% while volatility for the month is 5.58%. MacroGenics, Inc. (NASDAQ:MGNX) monthly performance is -15.17%. MacroGenics, Inc. (NASDAQ:MGNX) on 20 April, announced the presentation of pre-clinical data for Dual-Affinity Re-Targeting (DART(R)) molecules that target DR5 at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA. In addition, MacroGenics’ collaboration partner, Pfizer Inc., presented pre-clinical data on a DART molecule that simultaneously targets P-cadherin and CD3.